Goal-weight maintenance with behavioral consolidation
Notably, the superiority of subcutaneously administered semaglutide over other anti-diabetic drugs in reducing body weight was also observed (WMD: 2.65 kg, 95% CI: 3.49 to 1.81, and WMD: 3.78 kg, 95% CI: 4.71 to 2.85, for 0.5 and 1 mg, respectively)
The RADIANCE global program studied the Paradise system in three independently powered, sham-controlled, randomized clinical trials in over 500 patients with uncontrolled hypertension: RADIANCE II and RADIANCE-HTN SOLO, which studied patients with mild-moderate hypertension in an off-meds setting, and RADIANCE-HTN TRIO, which studied patients with resistant hypertension on standardized triple antihypertensive therapy
This effect is thought to be mediated through GLP-1 receptors in the cardiovascular system and is generally not clinically significant, though patients with certain arrhythmias or those sensitive to heart rate changes should be monitored
Denial of coverage for GLP-1s, either in structure, as with Medicare, or by plan sponsors, should not be solved by providing patients a less safe alternative